|Videos|January 24, 2022
SABCS 2021: Updates in Metastatic Breast Cancer
Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.
Advertisement
Data from the following clinical trials are discussed:
- GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with HER2–positive metastatic breast cancer: subgroup analyses from the randomized phase 3 study DESTINYBreast03
- GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial pyrotinib vs lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer
- GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor (HR)–positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: latest updates from the SUMMIT trial
- P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2+ metastatic breast cancer: results from a phase I study
- P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy for HER2+ breast cancer: results from a phase 1 study
- PD8-07: Evaluation of tucatinib + paclitaxel + pertuzumab + trastuzumab followed by AC (doxorubicin hydrochloride, cyclophosphamide) in high-risk HER2+ stage II/III breast cancer: results from the I-SPY2 trial
Advertisement
Related to this article
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML
4
Dive Into Key Data and Presentations From EHA 2026
5